Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 86386 refers to a qualitative screening test for Nuclear Matrix Protein 22 (NMP22). This test is specifically utilized in patients presenting with hematuria, which is the presence of blood in the urine. The primary purpose of the NMP22 test is to assist healthcare providers in distinguishing between hematuria caused by bladder cancer and hematuria resulting from other non-malignant conditions. NMP22 is a protein that resides within the cell nucleus, and its levels can be indicative of malignancy. In cases of bladder cancer, malignant neoplasms lead to an increase in intracellular NMP22 levels, which subsequently results in the shedding of this protein into the urine. To perform the test, a urine sample is collected from the patient, and a specialized test kit designed for NMP22 is employed to detect the presence or absence of the protein in the urine. Additionally, the test estimates the concentration of NMP22, with a level exceeding 7 being suggestive of a potential bladder malignancy. This screening test plays a crucial role in the early detection and diagnosis of bladder cancer, thereby facilitating timely intervention and management.
© Copyright 2026 Coding Ahead. All rights reserved.
The NMP22 qualitative screening test is indicated for patients who present with hematuria. The specific conditions or symptoms that warrant this test include:
The procedure for conducting the NMP22 qualitative screening test involves several key steps, which are outlined as follows:
Post-procedure care following the NMP22 qualitative screening test typically involves monitoring the patient for any immediate reactions to the test. Additionally, healthcare providers will discuss the results with the patient, particularly if the NMP22 level is elevated. If the test suggests a potential bladder malignancy, further diagnostic procedures, such as cystoscopy or imaging studies, may be recommended to confirm the diagnosis and determine the appropriate course of action. It is essential for patients to follow up with their healthcare provider to discuss the implications of the test results and any necessary next steps in their care.
| Short Descr | NUCLEAR MATRIX PROTEIN 22 | Medium Descr | NUCLEAR MATRIX PROTEIN 22 NMP22 QUALITATIVE | Long Descr | Nuclear Matrix Protein 22 (NMP22), qualitative | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | Yes | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 235 - Other Laboratory |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2012-01-01 | Added | Added |
| 1992-12-31 | Deleted | Code deleted. |
Get instant expert-level medical coding assistance.